[go: up one dir, main page]

BR9803168A - Tratamento de parada cardìaca congestiva. - Google Patents

Tratamento de parada cardìaca congestiva.

Info

Publication number
BR9803168A
BR9803168A BR9803168-6A BR9803168A BR9803168A BR 9803168 A BR9803168 A BR 9803168A BR 9803168 A BR9803168 A BR 9803168A BR 9803168 A BR9803168 A BR 9803168A
Authority
BR
Brazil
Prior art keywords
treatment
growth hormone
congestive heart
cardiac arrest
administering
Prior art date
Application number
BR9803168-6A
Other languages
English (en)
Inventor
Raymond Francis Kauffman
Alan David Palkowitz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9803168A publication Critical patent/BR9803168A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Patente de Invenção: <B>"TRATAMENTO DE PARADA CARDìACA CONGESTIVA"<D>. A invenção provê métodos para a modulação de função cardíaca através da administração de um secretagogo de hormónio de crescimento, que resulta em um aumento nos níveis de hormónio de crescimento endógeno. São também providos processos para o tratamento de insuficiência cardíaca congestiva através da administração de um secretagogo de hormónio de crescimento. São ainda providos processos para o tratamento de insuficiência cardíaca congestiva através da administração de um secretagogo de hormónio de crescimento em combinação com um hormónio de liberação de hormónio de crescimento, ou em combinação com um agente anti-hipertensivo, diurético, ou outros agentes apropriados.
BR9803168-6A 1997-08-19 1998-08-18 Tratamento de parada cardìaca congestiva. BR9803168A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5613597P 1997-08-19 1997-08-19

Publications (1)

Publication Number Publication Date
BR9803168A true BR9803168A (pt) 2000-01-11

Family

ID=22002400

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9803168-6A BR9803168A (pt) 1997-08-19 1998-08-18 Tratamento de parada cardìaca congestiva.

Country Status (7)

Country Link
EP (1) EP0898963A3 (pt)
JP (1) JP2001515045A (pt)
AU (1) AU9471598A (pt)
BR (1) BR9803168A (pt)
CA (1) CA2300848A1 (pt)
WO (1) WO1999008697A1 (pt)
ZA (1) ZA987383B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
WO2000010565A1 (en) * 1998-08-18 2000-03-02 Eli Lilly And Company Growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
AU2001274601A1 (en) * 2000-06-23 2002-01-02 Kaken Pharmaceutical Co., Ltd. Preventives or remedies for heart failure
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
ATE332307T1 (de) 2002-04-09 2006-07-15 Lilly Co Eli Wachstumhormonsekretionsförderer
WO2004014412A1 (ja) * 2002-08-09 2004-02-19 Kaken Pharmaceutical Co., Ltd. 心筋細胞保護剤
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
GEP20084420B (en) 2004-03-23 2008-07-10 Pfizer Prod Inc Use of imidazole compounds for the treatment of neurodegenerative disorders
CN101282941A (zh) 2005-09-22 2008-10-08 辉瑞产品公司 用于治疗神经障碍的咪唑类化合物
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
EA035256B1 (ru) 2013-07-18 2020-05-21 Новартис Аг Ингибиторы аутотаксинов, содержащие гетероарил-бензил-амидное ядро
GB202013383D0 (en) * 2020-08-26 2020-10-07 Givaudan Sa Process

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
RO115804B1 (ro) * 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
AU6772996A (en) * 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
SE9703929D0 (sv) * 1996-11-22 1997-10-28 Pharmacia & Upjohn Ab Therapeutical use and method

Also Published As

Publication number Publication date
EP0898963A2 (en) 1999-03-03
EP0898963A3 (en) 2003-07-09
WO1999008697A1 (en) 1999-02-25
AU9471598A (en) 1999-03-08
ZA987383B (en) 2000-02-17
CA2300848A1 (en) 1999-02-25
JP2001515045A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
BR9803168A (pt) Tratamento de parada cardìaca congestiva.
WO1997036609A3 (en) Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest
BR9915134A (pt) Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição
BR9911444A (pt) Agentes de tingimento para o tingimento de fibras de queratina
GT199800126A (es) Terapia de combinacion.
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
BR0212080A (pt) composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
EA199900553A1 (ru) Чрескожная терапевтическая система
PT831910E (pt) Terapia de combinacao a base de um antagonista epoxi-esteroidal de aldosterona e um antagonista de angiotensina ii para o tratamento de ataque cardiaco congestivo
PT100323A (pt) Dispositivo para a reducao das sensacoes durante a administracao iontoforetica de um agente terapeutico
BG102022A (bg) Дозиращ инхалатор за салметерол
BR9811094A (pt) Agente terapêutico para tumores linfáticos
DE69814394D1 (de) Verwendung von levobupivacain
CO4520286A1 (es) Procedimiento para preparar clorhidrato de 1-(2 -desoxi-2 , 2 -difluoro-d-ribofuranosil)-4-aminopirimidin-2-ona
PT804229E (pt) Utilizacao de amlodipina de um dos seus sais ou defelodipina em combinacao com um inibidor da en zima de conversao da angiotensina (ace) para no fabrico de um medicamento destinado ao tratamento da insuficiencia cardiaca congestiva nao isquemica
DE69821498D1 (de) Verwendung von amifostin
DK0825865T3 (da) Transdermalt, terapeutisk system for administrering af testosteron eller testosteronderivat
PH23818A (en) Enhancement of activity of alpha-adrenoceptor antagonists
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
BR9713514A (pt) Novo uso de creatina
AU584333B2 (en) Method of medical treatment of human viral diseases utilizing 1-```-d-ribofuranosyl-1,2,4-triazole-3- carboxamide
UY24063A1 (es) Empleo de concentrados con contenido de factor von willebrand (vwf) como terapia de combinacion en la terapia con antitromboticos y fibrinoliticos
ES2177769T3 (es) Derivado de aminotetralina para la terapia de trastornos cardiovascu lares.
WO1999064065A3 (en) Tumour therapy and imaging

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1894 DE 24/04/2007.